Medicenna Therapeutics Past Earnings Performance
Past criteria checks 0/6
Medicenna Therapeutics's earnings have been declining at an average annual rate of -15.1%, while the Biotechs industry saw earnings growing at 13.8% annually.
Key information
-15.1%
Earnings growth rate
0.05%
EPS growth rate
| Biotechs Industry Growth | 51.1% |
| Revenue growth rate | n/a |
| Return on equity | -82.8% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
We Think Medicenna Therapeutics (TSE:MDNA) Needs To Drive Business Growth Carefully
Oct 18
Medicenna Therapeutics (TSE:MDNA) Is In A Good Position To Deliver On Growth Plans
Jun 14Companies Like Medicenna Therapeutics (TSE:MDNA) Are In A Position To Invest In Growth
Feb 28Here's Why We're Not Too Worried About Medicenna Therapeutics' (TSE:MDNA) Cash Burn Situation
Nov 08Is Medicenna Therapeutics (TSE:MDNA) In A Good Position To Deliver On Growth Plans?
Mar 01We're Hopeful That Medicenna Therapeutics (TSE:MDNA) Will Use Its Cash Wisely
Aug 07Will Medicenna Therapeutics (TSE:MDNA) Spend Its Cash Wisely?
Apr 14We're Hopeful That Medicenna Therapeutics (TSE:MDNA) Will Use Its Cash Wisely
Dec 30
Revenue & Expenses BreakdownBeta
How Medicenna Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -15 | 6 | 11 |
| 30 Sep 23 | 0 | -12 | 7 | 10 |
| 30 Jun 23 | 0 | -9 | 7 | 10 |
| 31 Mar 23 | 0 | -10 | 7 | 9 |
| 31 Dec 22 | 0 | -9 | 8 | 9 |
| 30 Sep 22 | 0 | -13 | 8 | 9 |
| 30 Jun 22 | 0 | -20 | 8 | 13 |
| 31 Mar 22 | 0 | -23 | 8 | 15 |
| 31 Dec 21 | 0 | -25 | 8 | 17 |
| 30 Sep 21 | 0 | -26 | 8 | 17 |
| 30 Jun 21 | 0 | -21 | 8 | 13 |
| 31 Mar 21 | 0 | -17 | 7 | 11 |
| 31 Dec 20 | 0 | -14 | 5 | 9 |
| 30 Sep 20 | 0 | -11 | 4 | 8 |
| 30 Jun 20 | 0 | -9 | 3 | 7 |
| 31 Mar 20 | 0 | -8 | 2 | 6 |
| 31 Dec 19 | 0 | -7 | 2 | 4 |
| 30 Sep 19 | 0 | -6 | 2 | 4 |
| 30 Jun 19 | 0 | -5 | 2 | 3 |
| 31 Mar 19 | 0 | -5 | 2 | 3 |
| 31 Dec 18 | 0 | -5 | 2 | 3 |
| 30 Sep 18 | 0 | -5 | 2 | 3 |
| 30 Jun 18 | 0 | -6 | 2 | 4 |
| 31 Mar 18 | 0 | -7 | 2 | 5 |
| 31 Dec 17 | 0 | -11 | 2 | 6 |
| 30 Sep 17 | 0 | -11 | 2 | 7 |
| 30 Jun 17 | 0 | -10 | 2 | 6 |
| 31 Mar 17 | 0 | -8 | 2 | 4 |
| 31 Dec 16 | 0 | -3 | 1 | 2 |
| 30 Sep 16 | 0 | -2 | 1 | 1 |
| 30 Jun 16 | 0 | -1 | 1 | 1 |
| 31 Mar 16 | 0 | -1 | 0 | 1 |
| 31 Mar 15 | 0 | -1 | 0 | 1 |
Quality Earnings: MDNA is currently unprofitable.
Growing Profit Margin: MDNA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MDNA is unprofitable, and losses have increased over the past 5 years at a rate of 15.1% per year.
Accelerating Growth: Unable to compare MDNA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MDNA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: MDNA has a negative Return on Equity (-82.76%), as it is currently unprofitable.